Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Gains from Investment Securities (2016 - 2024)

Historic Gains from Investment Securities for Avalo Therapeutics (AVTX) over the last 8 years, with Q4 2024 value amounting to $26.5 million.

  • Avalo Therapeutics' Gains from Investment Securities changed N/A to $26.5 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$9.6 million, marking a year-over-year increase of 8609.64%. This contributed to the annual value of -$121.6 million for FY2024, which is N/A changed from last year.
  • Per Avalo Therapeutics' latest filing, its Gains from Investment Securities stood at $26.5 million for Q4 2024.
  • In the past 5 years, Avalo Therapeutics' Gains from Investment Securities registered a high of $79.3 million during Q1 2024, and its lowest value of -$112.0 million during Q2 2024.
  • For the 3-year period, Avalo Therapeutics' Gains from Investment Securities averaged around -$5.8 million, with its median value being $376000.0 (2020).
  • The largest annual percentage gain for Avalo Therapeutics' Gains from Investment Securities in the last 5 years was 12418.05% (2020), contrasted with its biggest fall of 12418.05% (2020).
  • Avalo Therapeutics' Gains from Investment Securities (Quarter) stood at $376000.0 in 2020, then tumbled by 266.76% to -$627000.0 in 2021, then soared by 4320.1% to $26.5 million in 2024.
  • Its Gains from Investment Securities was $26.5 million in Q4 2024, compared to -$36.0 million in Q3 2024 and -$112.0 million in Q2 2024.